AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JAN 17 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Investigators at the M.D. Anderson Cancer Center may have devised a new way to target breast cancer cells that express a potent cancer gene.
"Overexpression of HER-2/neu proto-oncogene is found in many human cancers including 20% to 30% of breast cancer and is a predictor of poor prognosis," said investigator Z. Li, University of Texas, and the coauthors of a recent report.
Armed with knowledge about antisense (AS) complexes and the inhibitory properties of iron-responsive elements (IREs), which are known to block translation by binding to endogenous iron regulatory protein (IRP), Li and colleagues developed and tested three AS-IREs, labeled 1, 4, and 5, with the potential for suppressing HER-2/neu proto-oncogene expression. In vitro, each of the AS-IREs blocked translation when placed into the 5' untranslated region of a reporter gene.
"Using AS-IRE4 as our model, we demonstrated that it is regulated by iron, and importantly, such regulation is impaired in HER-2/neu-overexpressing breast cancer cells," reported Li and associates.
That same molecule was also drawn to the reporter gene of breast cancer cells that overly produced HER-2/neu, and researchers found it could guide reporter gene expression ...